NCT03543839View on ClinicalTrials.gov

Trial of Belimumab in Early Lupus

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Lupus Erythematosus, SystemicLupus Erythematosus
Interventions
BIOLOGICAL

Belimumab

Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years

BIOLOGICAL

Belimumab/Placebo

Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.

OTHER

Placebo

Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years

Trial Locations (1)

11030

RECRUITING

Feinstein Institute, Manhasset

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Northwell Health

OTHER

NCT03543839 - Trial of Belimumab in Early Lupus | Biotech Hunter | Biotech Hunter